Brief: Kyowa Kirin Announces Top-Line Data From Rocatinlimab Phase 3 Rocket Horizon Trial
25/09/2024 12:05
Sept 25 (Reuters) - Kyowa Kirin Co Ltd 4151.T :
* KYOWA KIRIN ANNOUNCES TOP-LINE DATA FROM ROCATINLIMAB
PHASE 3
ROCKET HORIZON TRIAL FOR ADULTS WITH MODERATE TO SEVERE ATOPIC
DERMATITIS
* KYOWA KIRIN CO LTD - HORIZON TRIAL MEETS CO-PRIMARY
ENDPOINTS AT
WEEK 24
Source text for Eikon: ID:nPn4v3Z8pa
Further company coverage: 4151.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia